Partner David Rosen participated in a question and answer session with Reuter’s Westlaw, “Q&A: Foley & Lardner’s David Rosen on Obstacles to Generic EpiPen,” on October 24, 2106. The article discussed obstacles to getting a generic version of Mylan’s EpiPen on the market and how the U.S. Food and Drug Administration (FDA) can hasten the process.
In response to whether or not the FDA can help generic products reach the market, Rosen said, “They could facilitate them by having a little bit more interaction with the applicants, i.e., allowing them to come in for a meeting so they can address the issues and concerns with the developmental process and so they can understand FDA’s expectations. That will also help FDA understand and appreciate the developmental work that’s being done. Companies can get a little more guidance on what they’re doing and how they can meet FDA’s expectations for approval.”
In response to whether or not the FDA can help generic products reach the market, Rosen said, “They could facilitate them by having a little bit more interaction with the applicants, i.e., allowing them to come in for a meeting so they can address the issues and concerns with the developmental process and so they can understand FDA’s expectations. That will also help FDA understand and appreciate the developmental work that’s being done. Companies can get a little more guidance on what they’re doing and how they can meet FDA’s expectations for approval.”
People
Related News
July 2, 2025
In the News
John Strom and Peter Tomasi Quoted on Shift in Environmental Policy
Foley & Lardner LLP attorneys John Strom and Peter Tomasi commented on changes to federal environmental rules in the Utility Dive article, "Federal agencies, including FERC and DOE, revoke environmental review rules."
June 30, 2025
In the News
Lynn Gandhi Assesses Midyear Takeaways from Major State and Local Tax Cases
Foley & Lardner LLP partner Lynn Gandhi is featured by Law360 for her takeaways on major state and local tax cases in the article, "Top State & Local Tax Cases Of 2025: Midyear Report."
June 27, 2025
In the News
Donald Schroeder Highlights FMCS Importance Amid Service's Uncertain Future
Foley & Lardner LLP partner Donald Schroeder described the Federal Mediation and Conciliation Services' (FMCS) importance in the Law360 article, "As Feds' Bargaining Mediator Ails, New Services Emerge."